APGE Chief Medical Officer Carl Dambkowski Sells $3.5M of Stock

On June 22, 2026, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, Inc. (NasdaqGM: APGE), sold 26,400 shares in a planned transaction. The shares were sold at an average price of $132.6, totaling approximately $3.5 million.

Insider Buying and Selling at Apogee Therapeutics, Inc.

In addition to Carl Dambkowski's recent transaction, other notable insider activities at Apogee Therapeutics include Chief Executive Officer Michael Thomas Henderson selling 80,000 shares at $132.54 on the same day. Earlier in June, Henderson also sold 20,000 shares at $83.38. Meanwhile, insiders like Mark McKenna and William Jones Jr. made small purchases on June 9, 2026.

Other Institutional Activity in Apogee Therapeutics

T. Rowe Price Investment Management, Inc. significantly increased its stake in Apogee Therapeutics by 7,568,528 shares, bringing its total to 10,300,984 shares valued at about $867 million. FMR LLC also added 1,037,253 shares, raising its holdings to 9,262,291 shares worth around $780 million. Venrock Adviser, LLC maintained its position with 8,493,321 shares valued at approximately $715 million. In contrast, Wellington Management Group LLP reduced its stake by 370,882 shares, totaling 4,375,703 shares valued at $368 million. BlackRock, Inc. also increased its holdings by 301,657 shares, totaling 4,085,651 shares worth about $344 million.

Apogee Therapeutics Stock Snapshot

Shares of Apogee Therapeutics traded near $132.88 on Thursday. The company has a market capitalization of approximately $9.99 billion. Despite being unprofitable, Apogee has a forward P/E ratio of -25.52 and a beta of 0.619, indicating lower volatility compared to the market. The stock's 52-week range is between $34.34 and $133.00, with a 50-day moving average of $84.76 and a 200-day moving average of $69.38.

Analysts Set New Price Targets

On June 24, 2026, Stifel and Mizuho both downgraded Apogee Therapeutics to a 'hold' rating, setting a price target of $135. Deutsche Bank, Citigroup, and UBS made similar moves on June 23, each assigning a 'hold' rating with a target of $135. Canaccord Genuity also downgraded the stock on June 22 with a target of $135.11. Overall, the consensus among 16 analysts remains a 'strong buy', with an average target price of $119.50.

About Apogee Therapeutics

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts. It focuses on developing novel biologics for treating various inflammatory and immunology conditions, including atopic dermatitis and asthma. The company is advancing several candidates in clinical trials, such as Zumilokibart (APG777) for atopic dermatitis and asthma, and other promising therapies. Apogee was founded in 2022 and is led by CEO Dr. Michael Thomas Henderson.

Bottom Line

The recent insider sales at Apogee Therapeutics reflect planned transactions by top executives. While the company remains unprofitable, it continues to develop promising treatments in the biotechnology sector. The recent analyst downgrades suggest cautious optimism, with a consensus 'strong buy' rating highlighting potential long-term growth. It's important to note that insider transactions and analyst ratings are backward-looking and may not reflect current market conditions.